No Data
No Data
US FDA Approves Easton Biopharma's Abbreviated New Drug Application for Anti-Hypertension Injection
Chengdu Easton Biopharmaceuticals (688513.SH): Nifedipine Hydrochloride Injection Obtains FDA Pharmaceutical Registration Approval in the USA.
Chengdu Easton Biopharmaceuticals (688513.SH) announced that its wholly-owned subsidiary, Chengdu Shuode Pharmaceutical Co., Ltd. (referred to as "Shuode Pharmaceutical"), recently received a notification from the U.S. Food and Drug Administration (FDA) that its simplified new drug application (ANDA) for Nicardipine Hydrochloride Injection, which was submitted by Shuode Pharmaceutical to the FDA, has been officially approved. Nicardipine Hydrochloride Injection is mainly composed of Nicardipine Hydrochloride and is indicated for the short-term treatment of hypertension when oral administration is not feasible.
Chengdu Easton Biopharmaceuticals (688513.SH): The company did not implement stock repurchases in August.
On September 3, Gelunhui reported that Chengdu Easton Biopharmaceuticals (688513.SH) announced that in August 2024, the company did not implement share repurchases. As of the end of August 2024, the company had repurchased a total of 3,316,769 shares through centralized auction trading, accounting for 1.8788% of the company's current total share capital. The highest purchase price was 56.05 yuan/share and the lowest was 28.12 yuan/share, with a total transaction amount of RMB 123,694,177.73 (excluding stamp duty, transaction commission, and other trading expenses).
Express News | Chengdu Easton Biopharmaceuticals: Subsidiary Shuode Pharmaceuticals' oral solution of Propiverine Hydrochloride obtained the pharmaceutical registration certificate.
chengdu easton biopharmaceuticals (688513.SH): The registration certificate of fluvoxamine maleate tablets for pharmaceutical has been obtained
Chengdu Easton Biopharmaceuticals (688513.SH) announced on September 2nd that its wholly-owned subsidiary, Chengdu Shuode Pharmaceutical Co., Ltd. (referred to as "Shuode Pharmaceutical"), recently received the "Pharmaceutical Registration Certificate" issued by the National Medical Products Administration. The main component of the fluoxetine maleate tablets is fluoxetine maleate, and it is indicated for: (1) depression; (2) obsessive-compulsive disorder.
Chengdu Easton Biopharmaceuticals (688513) 2024 Interim Report Review: New product sales volume gradually accelerating, Q2 revenue slightly exceeding expectations.
Disclosure: The company disclosed its 2024 interim report, with H1 revenue of 0.67 billion yuan (+20.56%) and a net income attributable to the mother of 0.146 billion yuan (+11.38%), with a non-GAAP net income of 0.114 billion yuan (+
No Data
No Data